Myeloproliferative neoplasms (MPNs) originate from genetically transformed hematopoietic
stem cells that retain the capacity for multilineage differentiation and effective myelopoiesis …

Abstract Background Philadelphia (Ph) chromosome-negative myeloproliferative neoplasms
(MPNs) are a heterogeneous group of hematopoietic stem cell clonal diseases. Most …

Mutations in the calreticulin (CALR) gene were recently discovered in patients with essential
thrombocythemia (ET) lacking the JAK2 V617F and MPL W515 mutations, but no information …

We studied the relationship between JAK2 (V617F) mutant allele burden and clinical
phenotype, disease progression and survival in patients with polycythemia vera (PV). The …

Activating mutations of MPL exon 10 have been described in a minority of patients with
idiopathic myelofibrosis (IMF) or essential thrombocythemia (ET), but their prevalence and …

Polycythemia vera (PV) and essential thrombocythemia (ET) constitute two of the three BCR-
ABL1-negative myeloproliferative neoplasms and are characterized by relatively long …

The aim of this study was to determine whether the burden of JAK2 V617F allele correlated
with major clinical outcomes in patients with polycythemia vera (PV). To this end, we …

1Guy's and St Thomas' NHS Foundation Trust, London, 2Russells Hall Hospital, Dudley,
West Midlands, 3Arrowe Park Hospital Arrowe Park Road Upton Wirral, 4Wellcome Trust …

Recent advances in our understanding of the pathogenesis of the Philadelphia chromosome-
negative myeloproliferative neoplasms, polycythaemia vera, essential thrombocythaemia …

An acquired somatic mutation in the JAK2 gene (JAK2-V617F) is present in the majority of
patients with myeloproliferative disorders (MPDs). Several phenotypic manifestations …